Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-3318-9709
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees86
OptionableNot Optionable
Myovant Sciences (NYSE:MYOV) Frequently Asked Questions
What is Myovant Sciences' stock symbol?
Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."
How were Myovant Sciences' earnings last quarter?
Myovant Sciences Ltd (NYSE:MYOV) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.99) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.93) by $0.06. View Myovant Sciences' Earnings History.
When is Myovant Sciences' next earnings date?
What price target have analysts set for MYOV?
5 brokerages have issued twelve-month target prices for Myovant Sciences' shares. Their forecasts range from $18.00 to $42.00. On average, they expect Myovant Sciences' stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Myovant Sciences.
What is the consensus analysts' recommendation for Myovant Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.
Has Myovant Sciences been receiving favorable news coverage?
Media stories about MYOV stock have trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myovant Sciences earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Myovant Sciences' key competitors?
Some companies that are related to Myovant Sciences include FibroGen (FGEN), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM) and Akcea Therapeutics (AKCA).
Who are Myovant Sciences' key executives?
Myovant Sciences' management team includes the folowing people:
- Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 59)
- Mr. Frank L. Karbe, Principal Financial & Accounting Officer (Age 50)
- Mr. Matthew Lang, Gen. Counsel & Sec. (Age 42)
- Ms. Julie Tran MBA, MSHR, VP of HR
- Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 50)
When did Myovant Sciences IPO?
(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.
How do I buy shares of Myovant Sciences?
Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Myovant Sciences' stock price today?
One share of MYOV stock can currently be purchased for approximately $18.29.
How big of a company is Myovant Sciences?
Myovant Sciences has a market capitalization of $1.24 billion. Myovant Sciences employs 86 workers across the globe.
What is Myovant Sciences' official website?
How can I contact Myovant Sciences?
Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-3318-9709 or via email at [email protected]
MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
